|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,400.00 JPY | +2.51% |
|
+2.17% | +14.04% |
| 02-06 | Japan's Nikkei rallies on earnings in unsteady trade before Sunday election | RE |
| 02-06 | Japanese drugmakers slump after Trump unveils discount drug website | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 16.41 | 19.01 | 19.56 | 14.44 | 16.36 | |||||
Return on Total Capital | 20.27 | 24.02 | 25.23 | 17.84 | 19.08 | |||||
Return On Equity % | 23.42 | 27.95 | 28.67 | 21.34 | 21.96 | |||||
Return on Common Equity | 23.42 | 27.95 | 28.67 | 21.34 | 21.96 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 65.25 | 66.18 | 62.2 | 62.81 | 71.01 | |||||
SG&A Margin | 12 | 10.24 | 8 | 10.13 | 9.41 | |||||
EBITDA Margin % | 42.14 | 45.29 | 44.82 | 42.37 | 49.01 | |||||
EBITA Margin % | 38.28 | 42.2 | 42.33 | 39.52 | 46.3 | |||||
EBIT Margin % | 38.28 | 42.2 | 42.33 | 39.52 | 46.3 | |||||
Income From Continuing Operations Margin % | 27.29 | 30.31 | 29.72 | 29.29 | 33.09 | |||||
Net Income Margin % | 27.29 | 30.31 | 29.72 | 29.29 | 33.09 | |||||
Net Avail. For Common Margin % | 27.29 | 30.31 | 29.72 | 29.29 | 33.09 | |||||
Normalized Net Income Margin | 23.68 | 26.22 | 26.35 | 24.96 | 28.99 | |||||
Levered Free Cash Flow Margin | 15.88 | 17.77 | 11.76 | 28.53 | 28.94 | |||||
Unlevered Free Cash Flow Margin | 15.89 | 17.78 | 11.76 | 28.53 | 28.94 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.69 | 0.72 | 0.74 | 0.58 | 0.57 | |||||
Fixed Assets Turnover | 2.8 | 3.08 | 3.41 | 2.75 | 2.72 | |||||
Receivables Turnover (Average Receivables) | 2.91 | 2.64 | 2.4 | 2.34 | 3.06 | |||||
Inventory Turnover (Average Inventory) | 1.55 | 1.72 | 1.9 | 1.46 | 1.32 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.54 | 3.25 | 3.15 | 4.74 | 5.53 | |||||
Quick Ratio | 2.68 | 2.53 | 2.4 | 3.68 | 4.59 | |||||
Operating Cash Flow to Current Liabilities | 0.87 | 0.85 | 0.58 | 1.42 | 1.54 | |||||
Days Sales Outstanding (Average Receivables) | 125.69 | 138.31 | 152.36 | 155.71 | 119.78 | |||||
Days Outstanding Inventory (Average Inventory) | 235.56 | 211.96 | 192 | 249.78 | 276.89 | |||||
Average Days Payable Outstanding | 112.64 | 126.99 | 118.09 | 149.07 | 106.34 | |||||
Cash Conversion Cycle (Average Days) | 248.62 | 223.27 | 226.27 | 256.42 | 290.32 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.15 | 1.35 | 0.99 | 0.83 | 0.57 | |||||
Total Debt / Total Capital | 1.14 | 1.33 | 0.98 | 0.82 | 0.57 | |||||
LT Debt/Equity | 0.47 | 0.8 | 0.54 | 0.4 | 0.24 | |||||
Long-Term Debt / Total Capital | 0.47 | 0.79 | 0.53 | 0.4 | 0.24 | |||||
Total Liabilities / Total Assets | 20.68 | 22.79 | 23.82 | 15.88 | 13.9 | |||||
EBIT / Interest Expense | 4.86K | 8.79K | 8.74K | 16.27K | -108K | |||||
EBITDA / Interest Expense | 5.35K | 9.43K | 9.26K | 17.44K | -115K | |||||
(EBITDA - Capex) / Interest Expense | 4.43K | 8.06K | 8.23K | 14.78K | -105K | |||||
Total Debt / EBITDA | 0.03 | 0.04 | 0.02 | 0.03 | 0.02 | |||||
Net Debt / EBITDA | -1.11 | -1.01 | -0.87 | -1.54 | -1.72 | |||||
Total Debt / (EBITDA - Capex) | 0.04 | 0.04 | 0.03 | 0.03 | 0.02 | |||||
Net Debt / (EBITDA - Capex) | -1.34 | -1.18 | -0.97 | -1.82 | -1.88 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.68 | 27.04 | 26.02 | -11.79 | 5.33 | |||||
Gross Profit, 1 Yr. Growth % | 22.22 | 28.85 | 18.45 | -10.93 | 19.07 | |||||
EBITDA, 1 Yr. Growth % | 39.92 | 36.54 | 24.73 | -16.61 | 21.82 | |||||
EBITA, 1 Yr. Growth % | 43.04 | 40.06 | 26.41 | -17.65 | 23.41 | |||||
EBIT, 1 Yr. Growth % | 43.04 | 40.06 | 26.41 | -17.65 | 23.41 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 36.29 | 41.1 | 23.58 | -13.08 | 19 | |||||
Net Income, 1 Yr. Growth % | 36.29 | 41.1 | 23.58 | -13.08 | 19 | |||||
Normalized Net Income, 1 Yr. Growth % | 43.43 | 40.64 | 26.65 | -16.44 | 22.35 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 36.24 | 41.09 | 23.57 | -13.08 | 18.99 | |||||
Accounts Receivable, 1 Yr. Growth % | 39.47 | 40.16 | 44.34 | -37.78 | 4.82 | |||||
Inventory, 1 Yr. Growth % | 9.38 | 13.56 | 39.92 | -6.41 | -12.22 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 12.13 | 18.36 | 9.81 | 8.81 | 4.96 | |||||
Total Assets, 1 Yr. Growth % | 16.68 | 24.54 | 21.52 | 3.36 | 14.27 | |||||
Tangible Book Value, 1 Yr. Growth % | 15.13 | 21.96 | 20 | 14.76 | 17.31 | |||||
Common Equity, 1 Yr. Growth % | 14.76 | 21.23 | 19.9 | 14.12 | 16.97 | |||||
Cash From Operations, 1 Yr. Growth % | -0.78 | 36.38 | -12.7 | 67.92 | 9.19 | |||||
Capital Expenditures, 1 Yr. Growth % | 7.6 | 15.65 | -5.07 | 14.89 | -29.93 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 6.12 | 42.2 | -16.63 | 113.99 | 6.87 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 6.08 | 42.18 | -16.62 | 113.94 | 6.86 | |||||
Dividend Per Share, 1 Yr. Growth % | 71.88 | 38.18 | 2.63 | 2.56 | 22.5 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 16.5 | 20.71 | 26.53 | 5.43 | -3.61 | |||||
Gross Profit, 2 Yr. CAGR % | 27.28 | 25.49 | 23.54 | 2.72 | 2.99 | |||||
EBITDA, 2 Yr. CAGR % | 53.41 | 38.22 | 30.5 | 1.98 | 0.79 | |||||
EBITA, 2 Yr. CAGR % | 55.66 | 41.54 | 33.06 | 2.03 | 0.81 | |||||
EBIT, 2 Yr. CAGR % | 55.66 | 41.54 | 33.06 | 2.03 | 0.81 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 51.89 | 38.67 | 32.05 | 3.64 | 1.71 | |||||
Net Income, 2 Yr. CAGR % | 52.37 | 38.67 | 32.05 | 3.64 | 1.71 | |||||
Normalized Net Income, 2 Yr. CAGR % | 57.31 | 42.03 | 33.47 | 2.87 | 1.11 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 52.31 | 38.64 | 32.04 | 3.63 | 1.7 | |||||
Accounts Receivable, 2 Yr. CAGR % | 18.78 | 39.82 | 42.24 | -5.23 | -19.24 | |||||
Inventory, 2 Yr. CAGR % | 7.42 | 11.45 | 26.06 | 14.43 | -9.36 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 15.66 | 15.2 | 14 | 9.31 | 6.86 | |||||
Total Assets, 2 Yr. CAGR % | 15.91 | 20.54 | 23.02 | 12.07 | 8.68 | |||||
Tangible Book Value, 2 Yr. CAGR % | 14.2 | 18.5 | 20.97 | 17.35 | 16.02 | |||||
Common Equity, 2 Yr. CAGR % | 13.87 | 17.95 | 20.56 | 16.97 | 15.54 | |||||
Cash From Operations, 2 Yr. CAGR % | 31.22 | 16.33 | 9.11 | 21.08 | 35.41 | |||||
Capital Expenditures, 2 Yr. CAGR % | -10.86 | 11.56 | 4.78 | 4.43 | -10.28 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 91.16 | 22.84 | 8.88 | 33.57 | 51.22 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 90.99 | 22.81 | 8.88 | 33.56 | 51.2 | |||||
Dividend Per Share, 2 Yr. CAGR % | 38.51 | 54.11 | 19.09 | 2.6 | 12.09 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 13.78 | 19.92 | 22.45 | 12.19 | 5.4 | |||||
Gross Profit, 3 Yr. CAGR % | 22.4 | 27.8 | 23.1 | 10.78 | 7.9 | |||||
EBITDA, 3 Yr. CAGR % | 42.22 | 47.57 | 33.57 | 12.4 | 8.21 | |||||
EBITA, 3 Yr. CAGR % | 44.94 | 50.27 | 36.3 | 13.39 | 8.71 | |||||
EBIT, 3 Yr. CAGR % | 44.94 | 50.27 | 36.3 | 13.39 | 8.71 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 42.93 | 48.2 | 33.45 | 14.87 | 8.53 | |||||
Net Income, 3 Yr. CAGR % | 43.47 | 48.52 | 33.45 | 14.87 | 8.53 | |||||
Normalized Net Income, 3 Yr. CAGR % | 46.05 | 51.54 | 36.71 | 14.18 | 8.99 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 43.39 | 48.48 | 33.42 | 14.86 | 8.52 | |||||
Accounts Receivable, 3 Yr. CAGR % | 13.28 | 25.52 | 41.31 | 7.97 | -1.99 | |||||
Inventory, 3 Yr. CAGR % | 2.84 | 9.43 | 20.23 | 14.14 | 4.75 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 20.14 | 16.55 | 13.38 | 12.24 | 7.84 | |||||
Total Assets, 3 Yr. CAGR % | 13.17 | 18.72 | 20.87 | 16.08 | 12.8 | |||||
Tangible Book Value, 3 Yr. CAGR % | 12.54 | 16.73 | 18.99 | 18.86 | 17.33 | |||||
Common Equity, 3 Yr. CAGR % | 12.3 | 16.27 | 18.59 | 18.38 | 16.97 | |||||
Cash From Operations, 3 Yr. CAGR % | 23.97 | 32.92 | 5.71 | 25.98 | 16.98 | |||||
Capital Expenditures, 3 Yr. CAGR % | 20.16 | -2.78 | 5.71 | 8.05 | -8.57 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 35.31 | 73.2 | 7.95 | 36.39 | 24 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 35.27 | 73.1 | 7.94 | 36.37 | 23.99 | |||||
Dividend Per Share, 3 Yr. CAGR % | 38.58 | 38.4 | 34.58 | 13.3 | 8.84 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 9.55 | 15.25 | 18.72 | 13.9 | 11.27 | |||||
Gross Profit, 5 Yr. CAGR % | 14.7 | 22.1 | 22.85 | 17.11 | 14.62 | |||||
EBITDA, 5 Yr. CAGR % | 26.5 | 37.16 | 37.41 | 27.29 | 19.34 | |||||
EBITA, 5 Yr. CAGR % | 28.26 | 40.56 | 40.06 | 28.71 | 20.81 | |||||
EBIT, 5 Yr. CAGR % | 28.26 | 40.56 | 40.06 | 28.71 | 20.81 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 28.06 | 41 | 38.47 | 28.45 | 19.71 | |||||
Net Income, 5 Yr. CAGR % | 28.57 | 41.41 | 38.79 | 28.61 | 19.71 | |||||
Normalized Net Income, 5 Yr. CAGR % | 28.44 | 41.78 | 40.88 | 29.79 | 21.17 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 28.49 | 41.33 | 38.74 | 28.59 | 19.69 | |||||
Accounts Receivable, 5 Yr. CAGR % | 9.81 | 16.22 | 24.08 | 12.17 | 12.97 | |||||
Inventory, 5 Yr. CAGR % | 2.68 | 2.4 | 11.57 | 11.41 | 7.38 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 14.14 | 17.52 | 17.65 | 13.6 | 10.73 | |||||
Total Assets, 5 Yr. CAGR % | 9.43 | 13.8 | 17.01 | 16.01 | 15.84 | |||||
Tangible Book Value, 5 Yr. CAGR % | 9.32 | 13.24 | 15.84 | 16.98 | 17.8 | |||||
Common Equity, 5 Yr. CAGR % | 9.38 | 12.98 | 15.54 | 16.55 | 17.36 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.65 | 48.45 | 17.8 | 28.05 | 16.72 | |||||
Capital Expenditures, 5 Yr. CAGR % | 25.44 | 17 | 13.75 | 0.05 | -1 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 25.14 | 50.61 | 24.05 | 56.11 | 23.53 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 25.12 | 50.68 | 24.02 | 56.04 | 23.52 | |||||
Dividend Per Share, 5 Yr. CAGR % | 25.98 | 34.4 | 30.43 | 22.78 | 25.09 |
- Stock Market
- Equities
- 4519 Stock
- Financials Chugai Pharmaceutical Co., Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















